U.S. markets closed
  • S&P 500

    4,266.49
    +24.65 (+0.58%)
     
  • Dow 30

    34,196.82
    +322.58 (+0.95%)
     
  • Nasdaq

    14,369.71
    +97.98 (+0.69%)
     
  • Russell 2000

    2,333.62
    +30.15 (+1.31%)
     
  • Crude Oil

    73.34
    +0.26 (+0.36%)
     
  • Gold

    1,775.00
    -8.40 (-0.47%)
     
  • Silver

    26.01
    -0.10 (-0.37%)
     
  • EUR/USD

    1.1939
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    1.4870
    0.0000 (0.00%)
     
  • GBP/USD

    1.3927
    -0.0036 (-0.26%)
     
  • USD/JPY

    110.8660
    -0.0960 (-0.09%)
     
  • BTC-USD

    34,767.09
    +1,483.83 (+4.46%)
     
  • CMC Crypto 200

    835.60
    +48.99 (+6.23%)
     
  • FTSE 100

    7,109.97
    +35.91 (+0.51%)
     
  • Nikkei 225

    28,875.23
    +0.34 (+0.00%)
     

Soliton Stock Rallies After $22.60/Share Buyout From AbbVie

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • AbbVie Inc (NYSE: ABBV) is making an opportunistic play to boost the aesthetics business by adding a long-delayed body sculpting product into the fold.

  • AbbVie’s Allergan Aesthetics unit will pay 0 million in cash to scoop up Soliton Inc (NASDAQ: SOLY) and Resonic, its sound-wave device that improves the appearance of cellulite.

  • Under the terms of the transaction, Allergan Aesthetics will pay $22.60 per share in cash for each outstanding share of Soliton.

  • The body sculpting offering will help add some heft to the Allergan Aesthetics brand, which includes cosmetic Botox as its most visible product.

  • AbbVie propped up the aesthetics business as part of its $63 billion buyout of Allergan last year, keeping Botox’s therapeutic indications under the AbbVie brand.

  • Allergan Aesthetics already has a product in CoolSculpting Elite. Still, the Soliton pickup adds a non-invasive option in Resonic, which also holds approval in tattoo removal alongside lasers and improves the appearance of fibrotic scars.

  • Cosmetic Botox cleared $447 million in the first quarter, a 44.7% Y/Y increase. The unit, on the whole, made $1.14 billion in sales on the quarter. Meanwhile, the overall AbbVie business cleared more than $13 billion in sales on the quarter, led once again by Humira at $3.9 billion.

  • Price Action: SOLY shares are up 23.7% at $22.27, while ABBV shares are up 0.31% at $116.12 during the market trading session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.